CAM
XENE icon

Connacht Asset Management’s Xenon Pharmaceuticals XENE Stock Holding History

Connacht Asset Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$280K Buy
8,204
+2,039
+33% +$76.3K 1.66% 33
2023
Q2 		$237K Sell
6,165
-226
-4% -$8.98K 0.32% 85
2023
Q1 		$229K Buy
+6,391
New +$236K 0.1% 126

Other funds holding XENE

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Connacht Asset Management's XENE Position: Q3 2023 in Review

Connacht Asset Management increased its Xenon Pharmaceuticals (XENE) stake by 33% in Q3 2023, buying an estimated $76.3K and bringing the position to 8,204 shares worth $280K. The position accounts for 1.66% of the portfolio, ranked #33.

Connacht Asset Management first reported a position in XENE in Q1 2023 and has held it in 3 quarters since. 180 funds tracked by Wall St. Rank hold XENE as of Q3 2023.

  • Connacht Asset Management held 8,204 shares of Xenon Pharmaceuticals worth $280K as of Q3 2023.
  • Connacht Asset Management bought 2,039 Xenon Pharmaceuticals shares in Q3 2023, an estimated $76.3K.
  • Xenon Pharmaceuticals made up 1.66% of Connacht Asset Management's portfolio in Q3 2023, its #33 holding.
  • Connacht Asset Management first reported a position in Xenon Pharmaceuticals in Q1 2023 and has held it in 3 quarters since.
  • 180 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2023.

Based on Connacht Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.